Regulation of IL-10 and IL-12 production and function in macrophages and dendritic cells

F1000Research

Volumn 4, Issue , 2015, Pages 1-13

  Ma, Xiaojing ^a,b   Yan, Wenjun ^a   Zheng, Hua ^a   Du, Qinglin ^a   Zhang, Lixing ^a   Ban, Yi ^b   Li, Na ^a   Wei, Fang ^a  

^a Shanghai Jiao Tong University   (China)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 12;

ANTIGEN PRESENTING CELL; CYTOKINE PRODUCTION; DENDRITIC CELL; HOST RESISTANCE; HUMAN; IMMUNOREGULATION; INFLAMMATION; MACROPHAGE; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION;

EID: 84970993205     PISSN: 20461402     EISSN: 1759796X     Source Type: Journal    
DOI: 10.12688/f1000research.7010.1     Document Type: Review

References (151)

1. Kobayashi M Fitz L Ryan M: Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med. 1989;170(3):827-45. 2504877 2189443
2. Trinchieri G: Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood. 1994;84(12):4008-27. 7994020
3. Grohmann U Belladonna ML Vacca C: Positive regulatory role of IL-12 in macrophages and modulation by IFN-gamma. J Immunol. 2001;167(1):221-7. 11418652 10.4049/jimmunol.167.1.221
4. Ma X Chow JM Gri G: The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells. J Exp Med. 1996;183(1):147-57. 8551218 10.1084/jem.183.1.147 2192398
5. Oppmann B Lesley R Blom B: Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13(5):715-25. 11114383 10.1016/S1074-7613(00)00070-4
6. Teng MW Bowman EP McElwee JJ: IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med. 2015;21(7):719-29. 26121196 10.1038/nm.3895
7. Collison LW Workman CJ Kuo TT: The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 2007;450(7169):566-9. 18033300 10.1038/nature06306 F1000 Recommendation
8. Sawant DV Hamilton K Vignali DA: Interleukin-35: Expanding Its Job Profile. J Interferon Cytokine Res. 2015;35(7):499-512. 25919641 10.1089/jir.2015.0015 4507123
9. Dixon KO van der Kooij SW Vignali DA: Human tolerogenic dendritic cells produce IL-35 in the absence of other IL-12 family members. Eur J Immunol. 2015;45(6):1736-47. 25820702 10.1002/eji.201445217 4617619
10. Grohmann U Belladonna ML Bianchi R: IL-12 acts directly on DC to promote nuclear localization of NF-kappaB and primes DC for IL-12 production. Immunity. 1998;9(3):315-23. 9768751 10.1016/S1074-7613(00)80614-7
11. Desai BB Quinn PM Wolitzky AG: IL-12 receptor. II. Distribution and regulation of receptor expression. J Immunol. 1992;148(10):3125-32. 1578139
12. Watford WT Hissong BD Bream JH: Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol Rev. 2004;202(1):139-56. 15546391 10.1111/j.0105-2896.2004.00211.x
13. Trinchieri G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3(2):133-46. 12563297 10.1038/nri1001
14. Collison LW Delgoffe GM Guy CS: The composition and signaling of the IL-35 receptor are unconventional. Nat Immunol. 2012;13(3):290-9. 22306691 10.1038/ni.2227 3529151 F1000 Recommendation
15. Wolf SF Temple PA Kobayashi M: Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol. 1991;146(9):3074-81. 1673147
16. D'Andrea A Rengaraju M Valiante NM: Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med. 1992;176(5):1387-98. 1357073 2119437
17. Snijders A Hilkens CM van der Pouw Kraan TC: Regulation of bioactive IL-12 production in lipopolysaccharide-stimulated human monocytes is determined by the expression of the p35 subunit. J Immunol. 1996;156(3):1207-12. 8557999
18. Grumont R Hochrein H O'Keeffe M: c-Rel regulates interleukin 12 p70 expression in CD8 + dendritic cells by specifically inducing p35 gene transcription. J Exp Med. 2001;194(8):1021-32. 11602633 10.1084/jem.194.8.1021 2193517 F1000 Recommendation
19. Homma Y Cao S Shi X: The Th2 transcription factor c-Maf inhibits IL-12p35 gene expression in activated macrophages by targeting NF-kappaB nuclear translocation. J Interferon Cytokine Res. 2007;27(9):799-808. 17892401 10.1089/jir.2007.0006
20. Liu J Cao S Herman LM: Differential regulation of interleukin (IL)-12 p35 and p40 gene expression and interferon (IFN)-gamma-primed IL-12 production by IFN regulatory factor 1. J Exp Med. 2003;198(8):1265-76. 14568984 10.1084/jem.20030026 2194226
21. Goriely S Demonté D Nizet S: Human IL-12(p35) gene activation involves selective remodeling of a single nucleosome within a region of the promoter containing critical Sp1-binding sites. Blood. 2003;101(12):4894-902. 12576336 10.1182/blood-2002-09-2851 F1000 Recommendation
22. Goriely S Molle C Nguyen M: Interferon regulatory factor 3 is involved in Toll-like receptor 4 (TLR4)- and TLR3-induced IL-12p35 gene activation. Blood. 2006;107(3):1078-84. 16219795 10.1182/blood-2005-06-2416 F1000 Recommendation
23. Kim S Elkon KB Ma X: Transcriptional suppression of interleukin-12 gene expression following phagocytosis of apoptotic cells. Immunity. 2004;21(5):643-53. 15539151 10.1016/j.immuni.2004.09.009 F1000 Recommendation
24. Chung EY Liu J Homma Y: Interleukin-10 expression in macrophages during phagocytosis of apoptotic cells is mediated by homeodomain proteins Pbx1 and Prep-1. Immunity. 2007;27(6):952-64. 18093541 10.1016/j.immuni.2007.11.014 2194654
25. Plevy SE Gemberling JH Hsu S: Multiple control elements mediate activation of the murine and human interleukin 12 p40 promoters: evidence of functional synergy between C/EBP and Rel proteins. Mol Cell Biol. 1997;17(8):4572-88. 9234715 10.1128/MCB.17.8.4572 232311
26. Murphy TL Cleveland MG Kulesza P: Regulation of interleukin 12 p40 expression through an NF-kappa B half-site. Mol Cell Biol. 1995;15(10):5258-67. 7565674 10.1128/MCB.15.10.5258 230773
27. Sanjabi S Hoffmann A Liou HC: Selective requirement for c-Rel during IL-12 P40 gene induction in macrophages. Proc Natl Acad Sci U S A. 2000;97(23):12705-10. 11058167 10.1073/pnas.230436397 18828
28. 2. J Immunol. 2001;167(5):2608-18. 11509602 10.4049/jimmunol.167.5.2608
29. Maruyama S Sumita K Shen H: Identification of IFN regulatory factor-1 binding site in IL-12 p40 gene promoter. J Immunol. 2003;170(2):997-1001. 12517966 10.4049/jimmunol.170.2.997
30. Zhu C Rao K Xiong H: Activation of the murine interleukin-12 p40 promoter by functional interactions between NFAT and ICSBP. J Biol Chem. 2003;278(41):39372-82. 12876285 10.1074/jbc.M306441200
31. Wang IM Contursi C Masumi A: An IFN-gamma-inducible transcription factor, IFN consensus sequence binding protein (ICSBP), stimulates IL-12 p40 expression in macrophages. J Immunol. 2000;165(1):271-9. 10861061 10.4049/jimmunol.165.1.271
32. Zhu C Gagnidze K Gemberling JH: Characterization of an activation protein-1-binding site in the murine interleukin-12 p40 promoter. Demonstration of novel functional elements by a reductionist approach. J Biol Chem. 2001;276(21):18519-28. 11279072 10.1074/jbc.M100440200
33. Mitsuhashi M Liu J Cao S: Regulation of interleukin-12 gene expression and its anti-tumor activities by prostaglandin E 2 derived from mammary carcinomas. J Leukoc Biol. 2004;76(2):322-32. 15123779 10.1189/jlb.1203641 2965202
34. Goodridge HS Harnett W Liew FY: Differential regulation of interleukin-12 p40 and p35 induction via Erk mitogen-activated protein kinase-dependent and -independent mechanisms and the implications for bioactive IL-12 and IL-23 responses. Immunology. 2003;109(3):415-25. 12807488 10.1046/j.1365-2567.2003.01689.x 1782981 F1000 Recommendation
35. Ma C Muranyi M Chu CH: Involvement of DNA-PKcs in the IL-6 and IL-12 response to CpG-ODN is mediated by its interaction with TRAF6 in dendritic cells. PLoS One. 2013;8(3):e58072. 23533581 10.1371/journal.pone.0058072 3606245 F1000 Recommendation
36. Wang S Chen Z Hu C: Hepatitis B virus surface antigen selectively inhibits TLR2 ligand-induced IL-12 production in monocytes/macrophages by interfering with JNK activation. J Immunol. 2013;190(10):5142-51. 23585678 10.4049/jimmunol.1201625 F1000 Recommendation
37. Gorgoni B Maritano D Marthyn P: C/EBP beta gene inactivation causes both impaired and enhanced gene expression and inverse regulation of IL-12 p40 and p35 mRNAs in macrophages. J Immunol. 2002;168(8):4055-62. 11937564 10.4049/jimmunol.168.8.4055 F1000 Recommendation
38. Hayes MP Wang J Norcross MA: Regulation of interleukin-12 expression in human monocytes: selective priming by interferon-gamma of lipopolysaccharide-inducible p35 and p40 genes. Blood. 1995;86(2):646-50. 7605994
39. Negishi H Fujita Y Yanai H: Evidence for licensing of IFN-gamma-induced IFN regulatory factor 1 transcription factor by MyD88 in Toll-like receptor-dependent gene induction program. Proc Natl Acad Sci U S A. 2006;103(41):15136-41. 17018642 10.1073/pnas.0607181103 1586247 F1000 Recommendation
40. Gautier G Humbert M Deauvieau F: A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J Exp Med. 2005;201(9):1435-46. 15851485 10.1084/jem.20041964 2213193 F1000 Recommendation
41. Koshiba R Yanai H Matsuda A: Regulation of cooperative function of the Il12b enhancer and promoter by the interferon regulatory factors 3 and 5. Biochem Biophys Res Commun. 2013;430(1):95-100. 23154183 10.1016/j.bbrc.2012.11.006 F1000 Recommendation
42. Negishi H Yanai H Nakajima A: Cross-interference of RLR and TLR signaling pathways modulates antibacterial T cell responses. Nat Immunol. 2012;13(7):659-66. 22610141 10.1038/ni.2307 F1000 Recommendation
43. Kim H Zhao Q Zheng H: A novel crosstalk between TLR4- and NOD2-mediated signaling in the regulation of intestinal inflammation. Sci Rep. 2015;5: 12018. 26153766 10.1038/srep12018 4495563
44. Powell JD Pollizzi KN Heikamp EB: Regulation of immune responses by mTOR. Annu Rev Immunol. 2012;30:39-68. 22136167 10.1146/annurev-immunol-020711-075024 3616892
45. He L Zang A Du M: mTOR regulates TLR-induced c-fos and Th1 responses to HBV and HCV vaccines. Virol Sin. 2015;30(3):174-89. 26122641 10.1007/s12250-015-3606-3 F1000 Recommendation
46. Wei WC Liu CP Yang WC: Mammalian target of rapamycin complex 2 (mTORC2) regulates LPS-induced expression of IL-12 and IL-23 in human dendritic cells. J Leukoc Biol. 2015;97(6):1071-80. 25877925 10.1189/jlb.2A0414-206RR F1000 Recommendation
47. Ma X Neurath M Gri G: Identification and characterization of a novel Ets-2-related nuclear complex implicated in the activation of the human interleukin-12 p40 gene promoter. J Biol Chem. 1997;272(16):10389-95. 9099678 10.1074/jbc.272.16.10389
48. Moore KW Vieira P Fiorentino DF: Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science. 1990;248(4960):1230-4. 2161559 10.1126/science.2161559
49. Fiorentino DF Bond MW Mosmann TR: Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med. 1989;170(6):2081-95. 2531194 10.1084/jem.170.6.2081 2189521
50. Maloy KJ Powrie F: Regulatory T cells in the control of immune pathology. Nat Immunol. 2001;2(9):816-22. 11526392 10.1038/ni0901-816
51. Moore KW de Waal Malefyt R Coffman RL: Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683-765. 11244051 10.1146/annurev.immunol.19.1.683
52. Fillatreau S Sweenie CH McGeachy MJ: B cells regulate autoimmunity by provision of IL-10. Nat Immunol. 2002;3(10):944-50. 12244307 10.1038/ni833 F1000 Recommendation
53. Roncarolo MG Gregori S Battaglia M: Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev. 2006;212:28-50. 16903904 10.1111/j.0105-2896.2006.00420.x
54. O'Garra A Vieira P: T H1 cells control themselves by producing interleukin-10. Nat Rev Immunol. 2007;7(6):425-8. 17525751 10.1038/nri2097
55. Trinchieri G: Interleukin-10 production by effector T cells: Th1 cells show self control. J Exp Med. 2007;204(2):239-43. 17296790 10.1084/jem.20070104 2118719
56. Maynard CL Weaver CT: Diversity in the contribution of interleukin-10 to T-cell-mediated immune regulation. Immunol Rev. 2008;226:219-33. 19161427 10.1111/j.1600-065X.2008.00711.x 2630587
57. Sabatos-Peyton CA Verhagen J Wraith DC: Antigen-specific immunotherapy of autoimmune and allergic diseases. Curr Opin Immunol. 2010;22(5):609-15. 20850958 10.1016/j.coi.2010.08.006 2977065
58. Mauri C Bosma A: Immune regulatory function of B cells. Annu Rev Immunol. 2012;30:221-41. 22224776 10.1146/annurev-immunol-020711-074934
59. O'Garra A Vieira P: Regulatory T cells and mechanisms of immune system control. Nat Med. 2004;10(8):801-5. 15286781 10.1038/nm0804-801
60. Tan JC Indelicato SR Narula SK: Characterization of interleukin-10 receptors on human and mouse cells. J Biol Chem. 1993;268(28):21053-9. 8407942
61. Liu Y Wei SH Ho AS: Expression cloning and characterization of a human IL-10 receptor. J Immunol. 1994;152(4):1821-9. 8120391
62. Kotenko SV Krause CD Izotova LS: Identification and functional characterization of a second chain of the interleukin-10 receptor complex. EMBO J. 1997;16(19):5894-903. 9312047 10.1093/emboj/16.19.5894 1170220
63. Spencer SD Di Marco F Hooley J: The orphan receptor CRF2-4 is an essential subunit of the interleukin 10 receptor. J Exp Med. 1998;187(4):571-8. 9463407 10.1084/jem.187.4.571 2212143
64. Donnelly RP Dickensheets H Finbloom DS: The interleukin-10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes. J Interferon Cytokine Res. 1999;19(6):563-73. 10433356 10.1089/107999099313695
65. Wehinger J Gouilleux F Groner B: IL-10 induces DNA binding activity of three STAT proteins (Stat1, Stat3, and Stat5) and their distinct combinatorial assembly in the promoters of selected genes. FEBS Lett. 1996;394(3):365-70. 8830676 10.1016/0014-5793(96)00990-8
66. Weber-Nordt RM Riley JK Greenlund AC: Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain. J Biol Chem. 1996;271(44):27954-61. 8910398 10.1074/jbc.271.44.27954
67. Riley JK Takeda K Akira S: Interleukin-10 receptor signaling through the JAK-STAT pathway. Requirement for two distinct receptor-derived signals for anti-inflammatory action. J Biol Chem. 1999;274(23):16513-21. 10347215 10.1074/jbc.274.23.16513
68. Roers A Siewe L Strittmatter E: T cell-specific inactivation of the interleukin 10 gene in mice results in enhanced T cell responses but normal innate responses to lipopolysaccharide or skin irritation. J Exp Med. 2004;200(10):1289-97. 15534372 10.1084/jem.20041789 2211912 F1000 Recommendation
69. Medzhitov R: TLR-mediated innate immune recognition. Semin Immunol. 2007;19(1):1-2. 22228983 10.1016/j.smim.2007.02.001 3252746
70. Iwasaki A Medzhitov R: Regulation of adaptive immunity by the innate immune system. Science. 2010;327(5963):291-5. 20075244 10.1126/science.1183021 3645875
71. Brightbill HD Plevy SE Modlin RL: A prominent role for Sp1 during lipopolysaccharide-mediated induction of the IL-10 promoter in macrophages. J Immunol. 2000;164(4):1940-51. 10657644 10.4049/jimmunol.164.4.1940
72. Liu YW Tseng HP Chen LC: Functional cooperation of simian virus 40 promoter factor 1 and CCAAT/enhancer-binding protein beta and delta in lipopolysaccharide-induced gene activation of IL-10 in mouse macrophages. J Immunol. 2003;171(2):821-8. 12847250 10.4049/jimmunol.171.2.821
73. Cao S Liu J Song L: The protooncogene c-Maf is an essential transcription factor for IL-10 gene expression in macrophages. J Immunol. 2005;174(6):3484-92. 15749884 10.4049/jimmunol.174.6.3484 2955976
74. Liu YW Chen CC Tseng HP: Lipopolysaccharide-induced transcriptional activation of interleukin-10 is mediated by MAPK- and NF-kappaB-induced CCAAT/enhancer-binding protein delta in mouse macrophages. Cell Signal. 2006;18(9):1492-500. 16413748 10.1016/j.cellsig.2005.12.001
75. Ananieva O Darragh J Johansen C: The kinases MSK1 and MSK2 act as negative regulators of Toll-like receptor signaling. Nat Immunol. 2008;9(9):1028-36. 18690222 10.1038/ni.1644 F1000 Recommendation
76. 2 induces macrophage IL-10 production and a regulatory-like phenotype via a protein kinase A-SIK-CRTC3 pathway. J Immunol. 2013;190(2):565-77. 23241891 10.4049/jimmunol.1202462 3620524
77. Kim SH Serezani CH Okunishi K: Distinct protein kinase A anchoring proteins direct prostaglandin E 2 modulation of Toll-like receptor signaling in alveolar macrophages. J Biol Chem. 2011;286(11):8875-83. 21247892 10.1074/jbc.M110.187815 3058957
78. Pattison MJ MacKenzie KF Arthur JS: Inhibition of JAKs in macrophages increases lipopolysaccharide-induced cytokine production by blocking IL-10-mediated feedback. J Immunol. 2012;189(6):2784-92. 22904308 10.4049/jimmunol.1200310 3443740
79. Sayi A Kohler E Toller IM: TLR-2-activated B cells suppress Helicobacter-induced preneoplastic gastric immunopathology by inducing T regulatory-1 cells. J Immunol. 2011;186(2):878-90. 21149607 10.4049/jimmunol.1002269
80. Agrawal S Gupta S: TLR1/2, TLR7, and TLR9 signals directly activate human peripheral blood naive and memory B cell subsets to produce cytokines, chemokines, and hematopoietic growth factors. J Clin Immunol. 2011;31(1):89-98. 20821041 10.1007/s10875-010-9456-8 3064903
81. Sun CM Deriaud E Leclerc C: Upon TLR9 signaling, CD5 + B cells control the IL-12-dependent Th1-priming capacity of neonatal DCs. Immunity. 2005;22(4):467-77. 15845451 10.1016/j.immuni.2005.02.008
82. Wagner M Poeck H Jahrsdoerfer B: IL-12p70-dependent Th1 induction by human B cells requires combined activation with CD40 ligand and CpG DNA. J Immunol. 2004;172(2):954-63. 14707068 10.4049/jimmunol.172.2.954
83. Schmidt NW Thieu VT Mann BA: Bruton's tyrosine kinase is required for TLR-induced IL-10 production. J Immunol. 2006;177(10):7203-10. 17082638 10.4049/jimmunol.177.10.7203
84. Saraiva M O'Garra A: The regulation of IL-10 production by immune cells. Nat Rev Immunol. 2010;10(3):170-81. 20154735 10.1038/nri2711
85. MacKenzie KF Pattison MJ Arthur JS: Transcriptional regulation of IL-10 and its cell-specific role in vivo. Crit Rev Immunol. 2014;34(4):315-45. 24941159 10.1615/CritRevImmunol.2014010694 F1000 Recommendation
86. Voll RE Herrmann M Roth EA: Immunosuppressive effects of apoptotic cells. Nature. 1997;390(6658):350-1. 9389474 10.1038/37022
87. D'Andrea A Aste-Amezaga M Valiante NM: Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med. 1993;178(3):1041-8. 8102388 10.1084/jem.178.3.1041 2191152
88. Aste-Amezaga M Ma X Sartori A: Molecular mechanisms of the induction of IL-12 and its inhibition by IL-10. J Immunol. 1998;160(12):5936-44. 9637507
89. Smith AM Qualls JE O'Brien K: A distal enhancer in Il12b is the target of transcriptional repression by the STAT3 pathway and requires the basic leucine zipper (B-ZIP) protein NFIL3. J Biol Chem. 2011;286(26):23582-90. 21566115 10.1074/jbc.M111.249235 3123121
90. Kobayashi T Matsuoka K Sheikh SZ: IL-10 regulates Il12b expression via histone deacetylation: implications for intestinal macrophage homeostasis. J Immunol. 2012;189(4):1792-9. 22786766 10.4049/jimmunol.1200042 3411910 F1000 Recommendation
91. Cao S Liu J Chesi M: Differential regulation of IL-12 and IL-10 gene expression in macrophages by the basic leucine zipper transcription factor c-Maf fibrosarcoma. J Immunol. 2002;169(10):5715-25. 12421951 10.4049/jimmunol.169.10.5715
92. Krausgruber T Blazek K Smallie T: IRF5 promotes inflammatory macrophage polarization and T H1-T H17 responses. Nat Immunol. 2011;12(3):231-8. 21240265 10.1038/ni.1990 F1000 Recommendation
93. Colombo MP Trinchieri G: Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 2002;13(2):155-68. 11900991 10.1016/S1359-6101(01)00032-6
94. Shi X Cao S Mitsuhashi M: Genome-wide analysis of molecular changes in IL-12-induced control of mammary carcinoma via IFN-gamma-independent mechanisms. J Immunol. 2004;172(7):4111-22. 15034023 10.4049/jimmunol.172.7.4111 2956987
95. Simpson-Abelson MR Purohit VS Pang WM: IL-12 delivered intratumorally by multilamellar liposomes reactivates memory T cells in human tumor microenvironments. Clin Immunol. 2009;132(1):71-82. 19395317 10.1016/j.clim.2009.03.516 2693480
96. Helms MW Prescher JA Cao YA: IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy. Cancer Immunol Immunother. 2010;59(9):1325-34. 20532883 10.1007/s00262-010-0860-y
97. Marzano AV Gasparini G Caputo R: Subcutaneous sarcoidosis following hypophysectomy for pituitary microadenoma inducing Cushing's disease. Int J Dermatol. 1998;37(10):798. 9802695 10.1046/j.1365-4362.1998.00525.x
98. Denies S Cicchelero L Van Audenhove I: Combination of interleukin-12 gene therapy, metronomic cyclophosphamide and DNA cancer vaccination directs all arms of the immune system towards tumor eradication. J Control Release. 2014;187:175-82. 24887014 10.1016/j.jconrel.2014.05.045
99. Vom Berg J Vrohlings M Haller S: Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection. J Exp Med. 2013;210(13):2803-11. 24277150 10.1084/jem.20130678 3865478
100. Vogt A Sievers E Lukacs-Kornek V: Improving immunotherapy of hepatocellular carcinoma (HCC) using dendritic cells (DC) engineered to express IL-12 in vivo. Liver Int. 2014;34(3):447-61. 23998316 10.1111/liv.12284
101. Miguel A Herrero MJ Sendra L: Comparative antitumor effect among GM-CSF, IL-12 and GM-CSF+IL-12 genetically modified tumor cell vaccines. Cancer Gene Ther. 2013;20(10):576-81. 23969885 10.1038/cgt.2013.54
102. He H Fan P Yin T: Local delivery of recombinant adenovirus expressing hepatitis B virus X protein and interleukin-12 results in antitumor effects via inhibition of hepatoma cell growth and intervention of tumor microenvironment. Int J Mol Med. 2012;30(3):599-605. 22710287 10.3892/ijmm.2012.1027
103. Malvicini M Ingolotti M Piccioni F: Reversal of gastrointestinal carcinoma-induced immunosuppression and induction of antitumoural immunity by a combination of cyclophosphamide and gene transfer of IL-12. Mol Oncol. 2011;5(3):242-55. 21515097 10.1016/j.molonc.2011.03.007
104. Kerkar SP Muranski P Kaiser A: Tumor-specific CD8 + T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res. 2010;70(17):6725-34. 20647327 10.1158/0008-5472.CAN-10-0735 2935308
105. Malvicini M Rizzo M Alaniz L: A novel synergistic combination of cyclophosphamide and gene transfer of interleukin-12 eradicates colorectal carcinoma in mice. Clin Cancer Res. 2009;15(23):7256-65. 19920110 10.1158/1078-0432.CCR-09-1861
106. Yuzhalin AE Kutikhin AG: Interleukin-12: clinical usage and molecular markers of cancer susceptibility. Growth Factors. 2012;30(3):176-91. 22515181 10.3109/08977194.2012.678843
107. Ramos CA Savoldo B Dotti G: CD19-CAR trials. Cancer J. 2014;20(2):112-8. 24667955 10.1097/PPO.0000000000000031 3979594 F1000 Recommendation
108. Chmielewski M Kopecky C Hombach AA: IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 2011;71(17):5697-706. 21742772 10.1158/0008-5472.CAN-11-0103 F1000 Recommendation
109. Zhang L Kerkar SP Yu Z: Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol Ther. 2011;19(4):751-9. 21285960 10.1038/mt.2010.313 3070103
110. Zhang L Feldman SA Zheng Z: Evaluation of γ-retroviral vectors that mediate the inducible expression of IL-12 for clinical application. J Immunother. 2012;35(5):430-9. 22576348 10.1097/CJI.0b013e31825898e8 3358728
111. King IL Segal BM: Cutting edge: IL-12 induces CD4 +CD25 - T cell activation in the presence of T regulatory cells. J Immunol. 2005;175(2):641-5. 16002658 10.4049/jimmunol.175.2.641 F1000 Recommendation
112. Oldenhove G Bouladoux N Wohlfert EA: Decrease of Foxp3 + Treg cell number and acquisition of effector cell phenotype during lethal infection. Immunity. 2009;31(5):772-86. 19896394 10.1016/j.immuni.2009.10.001 2814877 F1000 Recommendation
113. Feng T Cao AT Weaver CT: Interleukin-12 converts Foxp3 + regulatory T cells to interferon-γ-producing Foxp3 + T cells that inhibit colitis. Gastroenterology. 2011;140(7):2031-43. 21419767 10.1053/j.gastro.2011.03.009 3109200
114. Zhao J Zhao J Perlman S: Differential effects of IL-12 on Tregs and non-Treg T cells: roles of IFN-γ, IL-2 and IL-2R. PLoS One. 2012;7(9):e46241. 23029447 10.1371/journal.pone.0046241 3459844 F1000 Recommendation
115. Kerkar SP Goldszmid RS Muranski P: IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest. 2011;121(12):4746-57. 22056381 10.1172/JCI58814 3226001 F1000 Recommendation
116. Broderick L Brooks SP Takita H: IL-12 reverses anergy to T cell receptor triggering in human lung tumor-associated memory T cells. Clin Immunol. 2006;118(2-3):159-69. 16271513 10.1016/j.clim.2005.09.008
117. Kilinc MO Aulakh KS Nair RE: Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8 + T effectors. J Immunol. 2006;177(10):6962-73. 17082611 10.4049/jimmunol.177.10.6962
118. Watkins SK Egilmez NK Suttles J: IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo. J Immunol. 2007;178(3):1357-62. 17237382 10.4049/jimmunol.178.3.1357 F1000 Recommendation
119. Curtsinger JM Lins DC Mescher MF: Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J Exp Med. 2003;197(9):1141-51. 12732656 10.1084/jem.20021910 2193970 F1000 Recommendation
120. O'Garra A Barrat FJ Castro AG: Strategies for use of IL-10 or its antagonists in human disease. Immunol Rev. 2008;223(1):114-31. 18613832 10.1111/j.1600-065X.2008.00635.x
121. Baglaenko Y Manion KP Chang NH: Suppression of autoimmunity by CD5 + IL-10-producing B cells in lupus-prone mice. Genes Immun. 2015;16(5):311-20. 25973757 10.1038/gene.2015.17 F1000 Recommendation
122. Frenkel D Huang Z Maron R: Neuroprotection by IL-10-producing MOG CD4+ T cells following ischemic stroke. J Neurol Sci. 2005;233(1-2):125-32. 15894335 10.1016/j.jns.2005.03.022 F1000 Recommendation
123. Gangi E Vasu C Cheatem D: IL-10-producing CD4 +CD25 + regulatory T cells play a critical role in granulocyte-macrophage colony-stimulating factor-induced suppression of experimental autoimmune thyroiditis. J Immunol. 2005;174(11):7006-13. 15905543 10.4049/jimmunol.174.11.7006 F1000 Recommendation
124. Lavasani S Dzhambazov B Nouri M: A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells. PLoS One. 2010;5(2):e9009. 20126401 10.1371/journal.pone.0009009 2814855 F1000 Recommendation
125. Matsushita T Yanaba K Bouaziz JD: Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest. 2008;118(10):3420-30. 18802481 10.1172/JCI36030 2542851 F1000 Recommendation
126. Yang M Deng J Liu Y: IL-10-producing regulatory B10 cells ameliorate collagen-induced arthritis via suppressing Th17 cell generation. Am J Pathol. 2012;180(6):2375-85. 22538089 10.1016/j.ajpath.2012.03.010 F1000 Recommendation
127. Yang S Li W Liu W: IL-10 gene modified dendritic cells induced antigen-specific tolerance in experimental autoimmune myocarditis. Clin Immunol. 2006;121(1):63-73. 16904381 10.1016/j.clim.2006.06.009 F1000 Recommendation
128. Brand S: Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut. 2009;58(8):1152-67. 19592695 10.1136/gut.2008.163667
129. Noguchi E Homma Y Kang X: A Crohn's disease-associated NOD2 mutation suppresses transcription of human IL10 by inhibiting activity of the nuclear ribonucleoprotein hnRNP-A1. Nat Immunol. 2009;10(5):471-9. 19349988 10.1038/ni.1722 2928218 F1000 Recommendation
130. Wang ZE Zheng S Corry DB: Interferon gamma-independent effects of interleukin 12 administered during acute or established infection due to Leishmania major. Proc Natl Acad Sci U S A. 1994;91(26):12932-6. 7809149 10.1073/pnas.91.26.12932 45554
131. Taylor AP Murray HW: Intracellular antimicrobial activity in the absence of interferon-gamma: effect of interleukin-12 in experimental visceral leishmaniasis in interferon-gamma gene-disrupted mice. J Exp Med. 1997;185(7):1231-9. 9104810 10.1084/jem.185.7.1231 2196266
132. Zilocchi C Stoppacciaro A Chiodoni C: Interferon gamma-independent rejection of interleukin 12-transduced carcinoma cells requires CD4 + T cells and Granulocyte/Macrophage colony-stimulating factor. J Exp Med. 1998;188(1):133-43. 9653090 10.1084/jem.188.1.133 2525540
133. Roilides E Tsaparidou S Kadiltsoglou I: Interleukin-12 enhances antifungal activity of human mononuclear phagocytes against Aspergillus fumigatus: implications for a gamma interferon-independent pathway. Infect Immun. 1999;67(6):3047-50. 10338518 96619
134. Hafner M Falk W Echtenacher B: Interleukin-12 activates NK cells for IFN-gamma-dependent and NKT cells for IFN-gamma-independent antimetastatic activity. Eur Cytokine Netw. 1999;10(4):541-8. 10586121
135. Afanasyeva M Wang Y Kaya Z: Interleukin-12 receptor/STAT4 signaling is required for the development of autoimmune myocarditis in mice by an interferon-gamma-independent pathway. Circulation. 2001;104(25):3145-51. 11748115 10.1161/hc5001.100629
136. Shi X Liu J Xiang Z: Gene expression analysis in Interleukin-12-induced suppression of mouse mammary carcinoma. Int J Cancer. 2004;110(4):570-8. 15122590 10.1002/ijc.20145 2957898
137. Meyaard L Hovenkamp E Otto SA: IL-12-induced IL-10 production by human T cells as a negative feedback for IL-12-induced immune responses. J Immunol. 1996;156(8):2776-82. 8609396
138. Portielje JE Lamers CH Kruit WH: Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses. Clin Cancer Res. 2003;9(1):76-83. 12538454
139. Gerosa F Paganin C Peritt D: Interleukin-12 primes human CD4 and CD8 T cell clones for high production of both interferon-gamma and interleukin-10. J Exp Med. 1996;183(6):2559-69. 8676077 10.1084/jem.183.6.2559 2192598
140. Wysocka M Robertson S Riemann H: IL-12 suppression during experimental endotoxin tolerance: dendritic cell loss and macrophage hyporesponsiveness. J Immunol. 2001;166(12):7504-13. 11390504 10.4049/jimmunol.166.12.7504 F1000 Recommendation
141. Foster SL Hargreaves DC Medzhitov R: Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature. 2007;447(7147):972-8. 17538624 10.1038/nature05836 F1000 Recommendation
142. He R Shepard LW Chen J: Serum amyloid A is an endogenous ligand that differentially induces IL-12 and IL-23. J Immunol. 2006;177(6):4072-9. 16951371 10.4049/jimmunol.177.6.4072 F1000 Recommendation
143. Waibler Z Kalinke U Will J: TLR-ligand stimulated interleukin-23 subunit expression and assembly is regulated differentially in murine plasmacytoid and myeloid dendritic cells. Mol Immunol. 2007;44(7):1483-9. 17052755 10.1016/j.molimm.2006.09.001
144. Gillessen S Carvajal D Ling P: Mouse interleukin-12 (IL-12) p40 homodimer: a potent IL-12 antagonist. Eur J Immunol. 1995;25(1):200-6. 7843232 10.1002/eji.1830250133
145. Ling P Gately MK Gubler U: Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity. J Immunol. 1995;154(1):116-27. 7527811
146. Heckel MC Wolfson A Slachta CA: Human breast tumor cells express IL-10 and IL-12p40 transcripts and proteins, but do not produce IL-12p70. Cell Immunol. 2011;266(2):143-53. 21055733 10.1016/j.cellimm.2010.09.010
147. Heinzel FP Hujer AM Ahmed FN: In vivo production and function of IL-12 p40 homodimers. J Immunol. 1997;158(9):4381-8. 9127002
148. Mattner F Ozmen L Podlaski FJ: Treatment with homodimeric interleukin-12 (IL-12) p40 protects mice from IL-12-dependent shock but not from tumor necrosis factor alpha-dependent shock. Infect Immun. 1997;65(11):4734-7. 9353058 175679
149. Piccotti JR Chan SY Li K: Differential effects of IL-12 receptor blockade with IL-12 p40 homodimer on the induction of CD4 + and CD8 + IFN-gamma-producing cells. J Immunol. 1997;158(2):643-8. 8992979
150. Pegram HJ Lee JC Hayman EG: Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 2012;119(18):4133-41. 22354001 10.1182/blood-2011-12-400044 3359735
151. Koneru M Purdon TJ Spriggs D: IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology. 2015;4(3):e994446. 25949921 10.4161/2162402X.2014.994446 4404840 F1000 Recommendation